Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continui
This study evaluates the effectiveness of a health systems strategy (the Systems Analysis and Improvement Approach - SAIA) that packages systems engineering tools (including cascade analysis, flow mapping, and continuous quality improvement) to optimize the management of opioid use disorder (MOUD) care cascade and impr
| Condition(s) | Opioid Use Disorder, Opioid Use Disorders |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This study evaluates the effectiveness of a health systems strategy (the Systems Analysis and Improvement Approach - SAIA) that packages systems engineering tools (including cascade analysis, flow mapping, and continuous quality improvement) to optimize the management of opioid use disorder (MOUD) care cascade and improve linkages between jails and clinical referral sites. The investigators will 1. study the effectiveness of SAIA on MOUD care cascade quality and continuity for patients receiving care in jail and exiting to referral clinics 2. explore determinants of adoption, implementation, and sustainment of SAIA-MOUD across implementation clinics, and 3. estimate the cost and cost-effectiveness of SAIA-MOUD |
| Who can participate | Inclusion Criteria: Implementation Outcomes (consented) Group 1: * clinic staff/providers at study clinics (JHS, OBOT, Pathways, Sound) * age 18+ Group 2: * current patients at SAIA clinic in the community (OBOT, Pathways, Sound) with jail involvement in the last 12 months * age 18+ Clinical Outcomes (de-identified data, non consented) Group 3: * receive MOUD treatment while incarcerated in King County Jails (WA). * age 18+ * on Medicaid * released to community Exclusion Criteria: Group 1 \& 2: * do not consent Group 3: * not on Medicaid |
| Ages | 18 Years to 110 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | University of Washington |
| Locations | Seattle, Washington, United States |
| Start date | 2024-11-21 |
| NCT ID | NCT06593353 |
| Official listing | https://clinicaltrials.gov/study/NCT06593353 |